Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155997 · ClinicalTrials.gov registry record · Phase 3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 5,637
- Enrollment target
- 20
- Study locations
NCT03155997 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 5,637 participants, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (101% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03155997, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,637 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Standard Adjuvant Endocrine Therapy
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center - Burbank
- City of Hope National Medical Center - Duarte
- California Cancer Associates Research and Excellence - Fresno
- Kaiser Permanente - Harbor City
- Loma Linda University School of Medicine - Loma Linda
- Cedars-Sinai Medical Center - Los Angeles
- Pacific Cancer Care - Monterey
- St. Joseph Hospital - Orange
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, P.C. - HOPE - Goodyear
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic Hospital - Phoenix
- The University of Arizona Cancer Center - Tucson
- Yuma Regional Cancer Center - Yuma
Arkansas
- St. Bernards Medical Center - Jonesboro
- Highlands Oncology Group - Springdale
Alabama
- University of Alabama Birmingham - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,637 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2029-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03155997
The ClinicalTrials.gov registry entry for NCT03155997 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 5,637 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,799-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (101% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Abemaciclib is the first listed.
NCT03155997 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03155997 about?
NCT03155997 is a clinical study titled "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer". The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
What is the current status of trial NCT03155997?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 5,637 participants. The study started on 2017-07-12. Estimated completion is 2029-05.
What conditions does trial NCT03155997 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03155997?
The interventions under investigation include: Abemaciclib (DRUG), Standard Adjuvant Endocrine Therapy (DRUG).
Who is sponsoring clinical trial NCT03155997?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03155997 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.